Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tioga Pharmaceuticals Inc.

www.tiogapharma.com

Latest From Tioga Pharmaceuticals Inc.

Pipeline Watch: Phase III Studies of CSL112 And RT-100 Imminent

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

IBS Trials Should Gauge Efficacy In Maintenance And Retreatment, FDA Says

Agency’s final guidance on clinical evaluation of irritable bowel syndrome drugs says sponsors should assess benefits of maintenance therapy and repeated courses of treatment in addition to short-term efficacy. The recommendations on clinical endpoints are “provisional” pending development of new patient-reported outcome measures.

BioPharmaceutical Drug Approval Standards

Recent Financings Of Private Companies, May 2012

START-UP's comprehensive review of emerging life science companies that have received venture funding during the month, including companies within the in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical equipment & supplies sectors.

BioPharmaceutical Medical Device

Ocera secures CE mark and seeks partners for IBS therapy Zysa

Ocera Therapeutics' spherical carbon adsorbent Zysa for the treatment of diarrhoea-predominant irritable bowel syndrome (D-IBS) is on two different paths in the US and in the EU, where the oral product has just received its CE Mark, denoting conformity with EU standards.

Gastrointestinal Neurology
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Tioga Pharmaceuticals Inc.
  • Senior Management
  • Stuart Collinson, PhD, Chmn. & CEO
    Allen Mangel, MD, PhD, CMO
  • Contact Info
  • Tioga Pharmaceuticals Inc.
    Phone: (858) 677-6077
    9393 Towne Center Dr., Ste. 200
    San Diego, CA 92121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register